特定类别的抗高血压药和阿尔茨海默病:基因型和高血压分层分析
Dehao Yang1, Ruting Wei2, Jinrong Zhu2
1Department of Neurology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310009, Zhejiang, China.
Molecular neurobiology
|March 10, 2026
概括
某些抗高血压药物类别,如ARBs,显示出对阿尔茨海默氏病 (AD) 风险的保护作用,特别是在APOE ε4载体中. 这表明,除了血压控制之外,还有个性化的AD预防策略.
科学领域:
- 神经科学和药理学 神经科学和药理学
- 遗传学和精准医学 遗传学和精准医学
背景情况:
- 抗高血压药物 (AHM) 可能通过脑血管或神经炎症途径影响阿尔茨海默氏病 (AD) 发病.
- 目前关于AHM和AD风险之间的关系的现有证据是相互矛盾的,需要对特定药物类别和遗传因素进行进一步调查.
研究的目的:
- 调查使用特定类型的抗高血压药物与患阿尔茨海默病的风险之间的因果关系.
- 检查高血压状态和阿波利波蛋白E epsilon 4 (APOE ε4) 基因型对AHM和AD风险之间的关系的潜在影响修饰.
主要方法:
- 综合门德尔随机化 (MR) 用于以纵向生存分析 (Cox回归) 来估计人口水平的因果效应,用于ADNI队列中的532名参与者.
- 分析根据高血压史和APOE ε4状态进行了分层,以评估效果的修改.
- MR分析评估了特定类别的因果影响,而生存分析则模拟了时间到AD转换.
主要成果:
- 总体而言,AHM的使用在高血压患者或APOE ε4载体中与AD风险没有显著的关联.
- 抗胰岛素II受体抑制剂 (ARBs) 显示出对AD风险的显著保护性关联,特别是在APOE ε4载体 (HR=0.32) 中.
- 对ARB,通道阻断剂 (CCB) 和β阻断剂 (BB) 的MR分析支持了因果保护作用,但对ACE抑制剂 (ACEI) 或化尿剂没有.
结论:
- 结果显示AHM对AD风险的类特异性影响,ARB,CCB和BB显示神经保护性益处.
- ARBs提供最强的保护,特别是在具有APOE ε4基因型的个体中,这表明ARBs的作用不仅仅是降低血压.
- 结果支持开发用于AD预防的精准医学方法,涉及对遗传脆弱人群的抗高血压药物的基因型引导选择.
相关概念视频
01:22Alzheimer's Disease: Treatment
1.1K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
81
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
81
01:28Hypertension IV: Drug Therapy and Lifestyle Modifications
800
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
800
01:29Pharmacogenomics: Identification of New Drug Targets
59
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
59
01:30Hypertension III: Clinical Manifestations and Diagnostic Studies
690
Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
690
01:26Alzheimer's Disease: Overview
1.9K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.9K